{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=35",
    "query": {
      "intervention": "Combination 400",
      "page": 35
    },
    "page_size": 10
  },
  "pagination": {
    "page": 35,
    "page_size": 10,
    "total_count": 1062,
    "total_pages": 107,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=36&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=34&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T14:57:52.806Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04812535",
      "title": "Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SCC - Squamous Cell Carcinoma of Skin"
      ],
      "interventions": [
        {
          "name": "Vilobelimab",
          "type": "DRUG"
        },
        {
          "name": "Vilobelimab + pembrolizumab combination therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "InflaRx GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-03-31",
      "completion_date": "2024-06-04",
      "has_results": true,
      "last_update_posted_date": "2025-02-11",
      "last_synced_at": "2026-11-09T14:57:52.806Z",
      "location_count": 6,
      "location_summary": "La Jolla, California • Aurora, Colorado • Miami, Florida + 3 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04812535"
    },
    {
      "nct_id": "NCT04938817",
      "title": "Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "coformulation pembrolizumab/quavonlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "MK-4830",
          "type": "BIOLOGICAL"
        },
        {
          "name": "coformulation favezelimab/pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "R-DXd",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2021-08-19",
      "completion_date": "2029-12-10",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-11-09T14:57:52.806Z",
      "location_count": 12,
      "location_summary": "Gilbert, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 7 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04938817"
    },
    {
      "nct_id": "NCT04458948",
      "title": "Non-comparative Trial of the Combination of HCQ and AZI in the Treatment of ICU Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Azithromycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of New Mexico",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2020-03-24",
      "completion_date": "2020-08-28",
      "has_results": true,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-11-09T14:57:52.806Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04458948"
    },
    {
      "nct_id": "NCT01329978",
      "title": "Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "Sofosbuvir",
          "type": "DRUG"
        },
        {
          "name": "RBV",
          "type": "DRUG"
        },
        {
          "name": "PEG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 332,
      "start_date": "2011-03",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2014-05-26",
      "last_synced_at": "2026-11-09T14:57:52.806Z",
      "location_count": 44,
      "location_summary": "Montgomery, Alabama • Jonesboro, Arkansas • Anaheim, California + 36 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Coronado",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01329978"
    },
    {
      "nct_id": "NCT03118843",
      "title": "Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C Virus Infection"
      ],
      "interventions": [
        {
          "name": "SOF/VEL/VOX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2017-04-25",
      "completion_date": "2018-03-19",
      "has_results": true,
      "last_update_posted_date": "2019-04-03",
      "last_synced_at": "2026-11-09T14:57:52.806Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • Palo Alto, California • Rialto, California + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Rialto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03118843"
    },
    {
      "nct_id": "NCT02825212",
      "title": "Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C",
        "Cryoglobulinemia"
      ],
      "interventions": [
        {
          "name": "Harvoni",
          "type": "DRUG"
        },
        {
          "name": "Epclusa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2016-02",
      "completion_date": "2019-07-19",
      "has_results": true,
      "last_update_posted_date": "2020-12-17",
      "last_synced_at": "2026-11-09T14:57:52.806Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02825212"
    },
    {
      "nct_id": "NCT00676130",
      "title": "Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cellulitis"
      ],
      "interventions": [
        {
          "name": "trimethoprim-sulfamethoxazole",
          "type": "DRUG"
        },
        {
          "name": "Cephalexin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Months and older"
      },
      "enrollment_count": 153,
      "start_date": "2007-05",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2012-08-14",
      "last_synced_at": "2026-11-09T14:57:52.806Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00676130"
    },
    {
      "nct_id": "NCT03259165",
      "title": "Nitroglycerin vs. Furosemide Using Lung Ultrasound Pilot Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure",
        "Heart Failure Acute",
        "Acute Cardiac Failure",
        "Acute Cardiac Pulmonary Edema"
      ],
      "interventions": [
        {
          "name": "Nitrates",
          "type": "DRUG"
        },
        {
          "name": "Loop Diuretics",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2017-12-14",
      "completion_date": "2021-12-31",
      "has_results": true,
      "last_update_posted_date": "2024-08-20",
      "last_synced_at": "2026-11-09T14:57:52.806Z",
      "location_count": 3,
      "location_summary": "Indianapolis, Indiana • Nashville, Tennessee",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03259165"
    },
    {
      "nct_id": "NCT00498836",
      "title": "Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Melanoma"
      ],
      "interventions": [
        {
          "name": "CP-4055",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib (Nexavar)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clavis Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2007-03",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2013-09-12",
      "last_synced_at": "2026-11-09T14:57:52.806Z",
      "location_count": 2,
      "location_summary": "Pittsburgh, Pennsylvania • San Antonio, Texas",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00498836"
    },
    {
      "nct_id": "NCT03207867",
      "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "NSCLC, Non Small Cell Lung Cancer",
        "RCC, Renal Cell Cancer",
        "Pancreatic Cancer",
        "Urothelial Cancer",
        "Head and Neck Cancer",
        "DLBCL, Diffused Large B Cell Lymphoma",
        "MSS, Microsatellite Stable Colon Cancer",
        "TNBC, Triple Negative Breast Cancer",
        "Melanoma",
        "mCRPC, Metastatic Castration Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "NIR178",
          "type": "DRUG"
        },
        {
          "name": "PDR001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 315,
      "start_date": "2017-08-28",
      "completion_date": "2023-02-14",
      "has_results": true,
      "last_update_posted_date": "2024-10-09",
      "last_synced_at": "2026-11-09T14:57:52.806Z",
      "location_count": 5,
      "location_summary": "Santa Monica, California • Tampa, Florida • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03207867"
    }
  ]
}